Insmed Inc (INSM)
Drugs • Health Care
July 23, 2026 Insmed Inc. to Announce Second-Quarter 2026 Financial Results on August 6 Insmed Inc. will release its financial results for Q2 2026 on August 6, followed by a conference call for investors. The call will provide insights into the company's future strategies and performance.
July 16, 2026 Insmed Inc. Reports Positive 12-Month Data for Treprostinil Palmitil Inhalation Powder in PAH Patients Insmed Inc. announced positive 12-month data for treprostinil palmitil inhalation powder (TPIP) in treating pulmonary arterial hypertension (PAH). The study demonstrated significant improvements in walking distance, risk scores, and overall safety, paving the way for Phase 3 trials.
June 23, 2026 Insmed Inc. Strengthens Leadership with Appointment of Samuele Butera Insmed Inc. has appointed Samuele Butera as Senior Vice President and General Manager of its Global Respiratory division. With over two decades of leadership experience, Butera aims to advance Insmed's respiratory portfolio and enhance patient centricity in therapeutic offerings.
June 04, 2026 Insmed Inc. Announces Inducement Grants to New Employees Insmed Inc. has granted inducement awards to 103 new employees as part of its strategy to attract talent in the biopharmaceutical sector. The inducement includes Restricted Stock Units and stock options, reflecting the company's commitment to employee engagement and retention.
May 27, 2026 Insmed Inc. to Showcase Innovations at 2026 Goldman Sachs Global Healthcare Conference Insmed Inc. will showcase its innovations at the 2026 Goldman Sachs Global Healthcare Conference in Miami. The company aims to discuss advancements in biopharmaceuticals, focusing on therapies for pulmonary and inflammatory conditions. Investors can access the live webcast and learn about Insmed's commitment to transforming patient lives.
May 07, 2026 Insmed Inc Reports Strong Q1 2026 Financial Results and Strategic Advances Insmed Inc's Q1 2026 results show a 230% revenue increase to $306 million, mainly due to the successful launch of BRINSUPRI. Despite a net loss of $163.6 million, the company is advancing its respiratory therapeutics and anticipating substantial revenue growth throughout the year.
May 06, 2026 Insmed Partners with Ty Pennington to Elevate Awareness of Bronchiectasis Insmed has teamed up with Ty Pennington for the 'Suspect Bronchiectasis' initiative to raise awareness about bronchiectasis. This campaign emphasizes the importance of early diagnosis and encourages patients to seek medical advice for lingering respiratory symptoms.
May 04, 2026 Insmed Inc. Reveals Promising Data at ATS 2026 Conference Insmed Inc. will present crucial data at the ATS 2026 Conference, including findings from the Phase 3b ENCORE study on ARIKAYCE for MAC lung infection. This underscores Insmed's commitment to advancing respiratory health and improving patient outcomes.
April 30, 2026 Insmed Inc. Gears Up for May Investor Conferences Insmed Inc. is set to participate in two major investor conferences in May 2026, focusing on their innovative therapies for serious diseases. The company aims to engage investors and share insights into its strategic direction and drug development advancements.
April 23, 2026 Insmed Inc. Prepares for First-Quarter 2026 Financial Results Conference Call Insmed Inc. will release its Q1 2026 financial results on May 7, 2026, followed by a conference call at 8:00 a.m. ET. Investors can join via phone or webcast for insights into the company's performance and future strategies.
April 07, 2026 Insmed's Phase 2b CEDAR Study Results: A Setback for Brensocatib in Hidradenitis Suppurativa Insmed's Phase 2b CEDAR study found that brensocatib did not meet primary or secondary efficacy endpoints for hidradenitis suppurativa, despite being well-tolerated. The company plans to discontinue the drug's development but aims to share insights from the study for future research.
March 23, 2026 Insmed Inc. Reports Promising Results from Phase 3b ENCORE Study of ARIKAYCE® for MAC Lung Disease Insmed Inc. announced promising results from its Phase 3b ENCORE study, highlighting ARIKAYCE's efficacy in treating MAC lung disease. The study demonstrated significant improvements in respiratory symptoms and culture conversion rates, paving the way for potential regulatory submissions later this year.
March 05, 2026 Insmed Inc. Announces Inducement Grants for New Employees Insmed Inc. has awarded inducement grants to 85 new employees to enhance its workforce and support strategic growth. The grants include restricted stock units and options, aligning employee success with the company's goals in biopharmaceutical innovation.
February 19, 2026 Insmed Inc. Reports Strong Financial Results for 2025, Announces Strategic Plans for 2026 Insmed Inc. reported a 153% revenue increase in Q4 2025, driven by the launch of BRINSUPRI and strong ARIKAYCE sales. The company plans significant investments in 2026 to expand its pipeline and commercial presence.
February 19, 2026 Insmed Inc. 2025 Annual Report: A Year of Transformative Growth and Strategic Investments Insmed Inc.'s 2025 annual report reveals a 66.7% increase in product revenues, driven by the success of BRINSUPRI. Despite operating losses, the company remains committed to R&D and strategic growth.
February 13, 2026 Insmed Inc. Set to Showcase Innovations at March 2026 Investor Conferences Insmed Inc. will present at two major investor conferences in March 2026, highlighting its innovative biopharmaceutical therapies and commitment to patient care. The conferences will be live-streamed, emphasizing transparency and engagement with stakeholders.
February 05, 2026 Insmed Inc. to Share Fourth-Quarter and Full-Year 2025 Financial Results Insmed Inc. will release its financial results for Q4 and full year 2025 on February 19, 2026. The company invites stakeholders to join a conference call to discuss performance insights and future projections.
January 28, 2026 Insmed Inc. Showcases Treprostinil Palmitil Inhalation Powder at PVRI 2026 Congress Insmed Inc. will present key findings on Treprostinil Palmitil Inhalation Powder (TPIP) at the PVRI 2026 Congress, emphasizing its potential in treating pulmonary arterial hypertension (PAH). The presentations will include insights from Phase 2 and Phase 3 studies, highlighting TPIP's efficacy and innovative delivery method.
January 09, 2026 Insmed Inc. Unveils Ambitious Plans at the 44th Annual J.P. Morgan Healthcare Conference At the 44th Annual J.P. Morgan Healthcare Conference, Insmed Inc. outlined its strategic vision for 2026, citing significant revenue growth and advancements in key therapies like BRINSUPRI and ARIKAYCE. The company aims to expand its therapeutic portfolio and enhance patient care, marking an exciting year ahead.
January 02, 2026 Insmed Inc. Set to Make Waves at the 2026 J.P. Morgan Healthcare Conference Insmed Inc. is set to present at the 2026 J.P. Morgan Healthcare Conference, focusing on its innovative therapies for serious diseases. The company's commitment to drug development and patient care is evident through its diverse pipeline and global presence.
December 30, 2025 Insmed Inc Faces Legal Scrutiny Following Disappointing Study Results Insmed Inc is facing an investigation by the Schall Law Firm for potential securities violations following disappointing results from the brensocatib study. The company's stock plummeted by 16.1% after announcing it would halt development of the drug. Investors are urged to participate in the investigation regarding possible misrepresentation.
December 17, 2025 Insmed Inc. Provides Clinical and Business Update: Disappointing Outcomes and New Opportunities Insmed Inc. faced setbacks with the Phase 2b BiRCh study for brensocatib, failing to meet efficacy endpoints. However, the company has acquired INS1148, an investigational monoclonal antibody that may enhance its drug pipeline focusing on serious respiratory diseases.
December 04, 2025 Insmed Inc. Announces Inducement Grants to New Employees Insmed Inc. recently granted inducement awards to 92 new hires, including stock options and restricted stock units, as part of its strategy to build a strong workforce. The awards align with Nasdaq guidelines and reflect Insmed's commitment to innovation and employee retention in the biopharmaceutical sector.
November 18, 2025 Insmed Inc. Secures Landmark Approval for BRINSUPRI® in the EU Insmed Inc. has received EU approval for BRINSUPRI® as the first treatment for non-cystic fibrosis bronchiectasis, addressing a significant unmet medical need. The drug showed promising efficacy in clinical trials, potentially transforming patient outcomes in Europe.
November 18, 2025 Insmed Inc. Celebrates European Approval of BRINSUPRI™ for Non-Cystic Fibrosis Bronchiectasis Insmed Inc. has received European Commission approval for BRINSUPRI™, the first treatment for non-cystic fibrosis bronchiectasis. This milestone offers hope to the 600,000 patients in Europe suffering from this chronic condition, promising improved health outcomes and reduced exacerbations.
November 13, 2025 Insmed Inc. Celebrates Fourth Annual Global Day of Good with Significant Employee Engagement Insmed Inc. celebrated its fourth annual Global Day of Good, involving over 1,200 employees worldwide in diverse volunteer efforts. This initiative highlights the company's commitment to social responsibility and community engagement year-round.
November 05, 2025 Insmed Inc. Announces Upcoming Investor Conferences for November and December 2025 Insmed Inc. has announced its participation in two major investor conferences in late 2025, focusing on its innovative therapies and strategic initiatives. The events will be webcast live, allowing broader access for stakeholders to learn about the company's advancements in treating serious diseases.
October 30, 2025 Insmed Inc Reports Third-Quarter Financial Results and Strategic Business Update Insmed Incorporated announced a robust Q3 2025 with significant revenue growth and the FDA approval of BRINSUPRI. The company is set for strategic launches and clinical milestones, reinforcing its commitment to innovative therapies.
October 30, 2025 Insmed Inc. Reports Strong Q3 2025 Results Amid New Product Launch Insmed Inc. achieved significant revenue growth in Q3 2025, reporting $142.3 million driven by the launch of BRINSUPRI and increased ARIKAYCE sales. However, the company faced higher net losses due to rising R&D and SG&A expenses as it expands its product pipeline.
October 23, 2025 Insmed Inc. Tops *Science*'s 2025 Biopharma Employers List for Fifth Consecutive Year Insmed Inc. has been recognized as the top biopharma employer by *Science* for the fifth consecutive year, reflecting its commitment to employee satisfaction and innovative research. The company's strong corporate culture and focus on developing therapies for serious diseases are key factors in this achievement.
October 17, 2025 Insmed Inc. Receives Positive CHMP Opinion for BRINSUPRI™ in Europe Insmed Inc. has received a positive opinion from the CHMP for BRINSUPRI™, the first potential treatment for non-cystic fibrosis bronchiectasis in Europe. This marks a significant milestone for patients and emphasizes the urgent need for effective therapies in this area.
October 16, 2025 Insmed Inc. to Showcase Phase 3 ASPEN Study Findings at CHEST 2025 Insmed Inc. will present key findings from its Phase 3 ASPEN study of BRINSUPRI™ at CHEST 2025, showcasing its efficacy in treating non-cystic fibrosis bronchiectasis. The presentations will include important analyses on symptom burden and CT outcomes, highlighting the potential impact of this innovative therapy.
October 15, 2025 Insmed Inc. to Announce Third-Quarter 2025 Financial Results Insmed Inc. is set to release its third-quarter financial results for 2025 on October 30. A conference call will follow to discuss the results and provide updates to investors. The company is recognized for its innovative therapies and commitment to patient care.
September 22, 2025 Insmed Inc. Set to Showcase Innovative Research at ERS Congress 2025 Insmed Inc. is set to present significant findings at the ERS Congress 2025, including new data on treprostinil palmitil inhalation powder for pulmonary arterial hypertension. The presentations highlight the company’s commitment to advancing respiratory medicine through innovative therapies.
September 05, 2025 Insmed Inc. Announces Inducement Grants for New Employees Insmed Inc. has granted inducement awards to 115 new employees under its 2025 Inducement Plan to attract top talent. This includes 70,742 restricted stock units and stock options, showcasing the company's dedication to employee engagement and long-term commitment.
August 21, 2025 Insmed Inc. Set to Present at Key September Investor Conferences Insmed Inc. is set to present at the Wells Fargo and Morgan Stanley investor conferences in September 2025, highlighting its innovative therapies and commitment to patient care. The presentations will be live-streamed, providing insights into the company's strategic vision and pipeline developments.
August 12, 2025 Insmed Inc. Achieves Historic FDA Approval for BRINSUPRI™: A Game-Changer for Non-Cystic Fibrosis Bronchiectasis Insmed has achieved FDA approval for BRINSUPRI™, the first therapy for non-cystic fibrosis bronchiectasis, a chronic lung disease affecting 500,000 patients in the U.S. This innovative treatment targets neutrophilic inflammation, offering hope for effective management and improved patient outcomes. The company also plans further international approvals and patient support initiatives.
August 07, 2025 Insmed Inc. Reports Q2 2025 Earnings: Growth Amidst Financial Challenges Insmed Inc. reported an 18.9% revenue increase in Q2 2025, driven by ARIKAYCE sales, despite significant cost rises and a net loss of $321.6 million. The company is advancing its product pipeline with promising developments in Brensocatib and other therapies, while facing regulatory challenges.
August 07, 2025 Insmed Inc. Reports Second-Quarter 2025 Financial Results and Business Progress Insmed Inc. reported an 18.9% revenue increase in Q2 2025, driven by impressive growth of ARIKAYCE. The company also achieved positive results in clinical trials and is preparing for the potential launch of brensocatib.
July 24, 2025 Insmed Inc. to Release Second-Quarter 2025 Financial Results Insmed Inc. will release its Q2 2025 financial results on August 7, 2025. A conference call will follow, offering insights into company performance and strategic direction. Investors can participate via phone or live stream.
June 11, 2025 Insmed Inc. Announces $750 Million Public Offering: A Strategic Move for Growth Insmed Inc. has announced a $750 million public offering aimed at funding its research and development initiatives, particularly for the therapy brensocatib. The offering is set to close on June 13, 2025, and reflects Insmed's commitment to expanding its therapeutic offerings and market presence.
June 11, 2025 Insmed Inc. Announces Major Public Offering of Common Stock Insmed Inc. has announced a public offering of common stock aimed at raising approximately $650 million to support its innovative therapies. This move reflects Insmed's commitment to advancing its research and development efforts in the biopharmaceutical sector. The offering, managed by Goldman Sachs and Leerink Partners, may further enhance the company's financial position.
June 10, 2025 Insmed Inc. Reports Positive Phase 2b Results for Treprostinil Palmitil Inhalation Powder in PAH Patients Insmed Inc. has unveiled encouraging results from its Phase 2b study of Treprostinil Palmitil Inhalation Powder for pulmonary arterial hypertension, achieving significant reductions in pulmonary vascular resistance and improvements in patient mobility. The company plans to pursue Phase 3 trials following these promising outcomes.
June 04, 2025 Insmed Inc. Announces Inducement Grants to New Employees Insmed Inc. has announced inducement awards for 150 new employees under its 2025 Inducement Plan, highlighting its commitment to attracting talent in the biopharmaceutical sector. The grants include Restricted Stock Units and stock options, reinforcing Insmed’s mission to innovate and improve patient outcomes.
May 28, 2025 Insmed Inc. to Present at Goldman Sachs Annual Global Healthcare Conference Insmed Inc. will present at the Goldman Sachs Annual Global Healthcare Conference on June 11, 2025. The company will showcase its commitment to innovative therapies and advancements in treating serious diseases, supported by a diverse research portfolio.
May 21, 2025 Insmed Inc. Unveils Promising Data for Brensocatib at ATS 2025 Conference At the ATS 2025 Conference, Insmed revealed significant findings from the Phase 3 ASPEN study on brensocatib, demonstrating its effectiveness in reducing exacerbations in bronchiectasis patients. The trial's data highlighted consistent safety and efficacy across various patient subgroups, presenting brensocatib as a potential game-changer in treatment options.
May 08, 2025 Insmed Inc. Reports Strong First-Quarter 2025 Results Amid Strategic Advancements Insmed Inc. announced its Q1 2025 results, showcasing a 22.9% revenue increase driven by ARIKAYCE. The company is advancing key clinical trials and preparing for product launches, including brensocatib, amidst a strategic push for growth.
May 08, 2025 Insmed Inc. Reports Q1 2025 Results: Growth in Revenues Amid Increased Expenses Insmed Inc. reports a 22.9% increase in Q1 2025 revenues, largely from ARIKAYCE sales, but also faces significant rising expenses leading to a net loss of $256.5 million. The company is focused on expanding its product pipeline, including brensocatib and INS1201, while navigating operational challenges.
April 29, 2025 Insmed Inc. to Showcase Innovations at BofA Securities 2025 Health Care Conference Insmed Inc. will present at the BofA Securities 2025 Health Care Conference on May 13, highlighting its advancements in transformative therapies for serious diseases. The event will be available via live webcast, promoting transparency and accessibility for stakeholders.
April 24, 2025 Insmed Inc. Announces Redemption of Convertible Senior Notes Insmed Inc. has announced the redemption of its remaining $569.5 million convertible senior notes due in 2028, effective June 6, 2025. This strategic move aims to optimize the company's capital structure, enhance financial flexibility, and support future growth.
April 23, 2025 Insmed Inc. Announces Breakthrough in Bronchiectasis Treatment: Positive Results from Phase 3 ASPEN Study of Brensocatib Published in NEJM Insmed Inc. announces positive results from the Phase 3 ASPEN study of brensocatib, showing significant reduction in pulmonary exacerbations for bronchiectasis patients. The study highlights brensocatib's potential as the first approved treatment for this chronic condition, currently under FDA review.
April 23, 2025 Insmed Inc. to Announce First-Quarter 2025 Financial Results Insmed Inc. is set to release its first-quarter 2025 financial results on May 8, 2025. Following the announcement, a conference call will provide updates on financial performance and drug development efforts.
March 25, 2025 Insmed Inc. Showcases Innovative Research at ATS 2025 Conference Insmed Inc. will present 11 abstracts at the ATS 2025 Conference, focusing on its innovative therapies for bronchiectasis and MAC lung disease. Highlights include new data on brensocatib and health economics related to MAC lung disease, showcasing Insmed's commitment to enhancing patient outcomes.
March 10, 2025 Insmed Inc. Announces Inducement Grants for New Employees Insmed Inc. has awarded stock options to 18 new employees as part of its strategy to attract talent in the biopharmaceutical sector. The inducement grants align employee interests with the company's long-term success, reinforcing Insmed's commitment to a people-first philosophy.
February 24, 2025 Insmed Inc. Receives Positive FDA Update on Brensocatib for Bronchiectasis Insmed Inc. announced a positive FDA update for brensocatib, indicating no advisory committee meeting is needed for its NDA. This treatment could be a breakthrough for bronchiectasis patients, addressing a significant unmet medical need.
February 20, 2025 Insmed Inc. 2024 Annual Report: A Year of Growth Amidst Challenges Insmed Inc.'s 2024 annual report reveals a 19.2% revenue growth reaching $363.7 million despite a rising net loss of $913.7 million. The company focuses on advancing its product pipeline, aiming to address unmet medical needs in rare diseases.
February 20, 2025 Insmed Inc. Reports Promising Financial Results and Strategic Advances for 2024 Insmed Inc. has reported a 19.2% increase in total revenues for 2024, driven largely by ARIKAYCE sales. Despite net losses due to heavy R&D investment, the company is poised for growth with upcoming product launches and clinical advancements.
February 15, 2025 SWOT Analysis of Insmed Inc in 2025 This SWOT analysis of Insmed Inc. in 2025 reveals its strengths in rare disease treatments and solid market presence, while also addressing significant weaknesses and threats. The company has opportunities for growth, particularly through international expansion and product development.
February 11, 2025 Insmed Inc. Set to Showcase Innovations at Upcoming Investor Conferences Insmed Inc. will present its innovative drug development pipeline at two major investor conferences in March 2025. The company is recognized for its commitment to patient-centric solutions and cutting-edge research in biopharmaceuticals.
February 10, 2025 Insmed Inc. Announces Fourth-Quarter and Full-Year 2024 Financial Results Conference Call Insmed Inc. will release its financial results for Q4 and full-year 2024 on February 20, 2025, followed by a conference call at 8:00 a.m. ET. Stakeholders can join via phone or webcast to gain insights into the company's performance and strategy.
February 07, 2025 Insmed Inc. Announces Inducement Grants to New Employees Insmed Inc. has awarded stock options to 66 new employees as part of its strategy to attract top talent. This initiative aligns with the company's commitment to innovation and employee engagement, reinforcing its position in the biopharmaceutical sector.
February 06, 2025 Insmed Inc Receives FDA's Priority Review for Brensocatib: A Potential Breakthrough in Bronchiectasis Treatment Insmed's brensocatib has received FDA Priority Review, marking a potential breakthrough for bronchiectasis treatment, affecting 500,000 patients in the U.S. The drug's efficacy is supported by Phase 3 trial data, with a target decision date of August 12, 2025.
October 31, 2024 Insmed Inc. Reports Q3 2024 Financial Results: Growth Amidst Challenges Insmed Inc. announced its Q3 2024 financial results, highlighting an 18.2% revenue increase driven by ARIKAYCE. Despite this growth, the company reported a net loss of $220.5 million, raising concerns about its financial sustainability amidst rising costs and ongoing R&D investments.
August 08, 2024 Insmed Inc. Reports Strong Revenue Growth in Q2 2024 Amid Increased Expenses Insmed Inc. reported a 17% revenue increase in Q2 2024, driven by strong ARIKAYCE sales, despite a net loss of $300.6 million due to rising expenses. The company is advancing its pipeline with promising candidates and strategic financing initiatives.
May 09, 2024 Insmed Inc. Reports Q1 2024 Financial Results: A Mixed Bag of Growth and Challenges Insmed Inc. announced its Q1 2024 financial results, revealing a 15.8% increase in product revenues to $75.5 million, primarily driven by ARIKAYCE sales. However, the company reported a net income loss of $157.0 million, highlighting ongoing operational challenges. Despite these hurdles, Insmed's strong cash position and robust product pipeline signal potential for future growth.